目的 評(píng)價(jià)參麥注射液對(duì)中晚期肺癌化療患者生活質(zhì)量的影響。方法 64例中晚期非小細(xì)胞肺癌患者，隨機(jī)分為治療組（32例）和對(duì)照組（32例）。對(duì)照組采用NP化療方案：第l、8天iv諾維本30 mg/m2；第l天靜脈滴注順鉑80～100 mg/m2，配合水化；1個(gè)療程3周。治療組化療方案同對(duì)照組，同時(shí)患者于化療前3 d開始靜脈滴注參麥注射液，50～100 mL/次，1 次/d，連用14 d。兩組患者共治療2個(gè)療程。于第1個(gè)療程第1天和第2個(gè)療程結(jié)束后15 d評(píng)價(jià)患者生活質(zhì)量。結(jié)果 治療后兩組患者軀體功能、角色功能、認(rèn)知功能、情緒功能、社會(huì)功能5個(gè)維度及整體生活質(zhì)量評(píng)分均較治療前明顯上升（P＜0.05），治療組軀體、角色、情緒功能和整體生活質(zhì)量評(píng)分均高于對(duì)照組（P＜0.05）；化療后兩組疲乏、疼痛、惡心嘔吐評(píng)分均明顯上升（P＜0.01，P＜0.05），治療組評(píng)分均低于對(duì)照組（P＜0.01）；治療組呼吸困難、失眠、食欲喪失、便秘評(píng)分低于對(duì)照組（P＜0.05）。結(jié)論 參麥注射液聯(lián)合化療能改善中晚期肺癌患者的生存質(zhì)量。

Objective To evaluate Shenmai Injection on life quality of the patients suffered from moderate and advanced stages non-small cell lung cancer treated by chemotherapy. Methods The patients (64 cases) diagnosed as moderate and advanced non-small cell carcinoma were randomly divided into treatment (32 cases) and control (32 cases) groups. The patients in the control group were adopted NP regimen: the patients were iv injected with Navelbine (NVB, 30 mg/m2) on the days 1 and 8, and iv dripped with Cis-platinum (DDP, 80—100 mg/m2) on the day 1. A course lasted for three weeks. The chemotherapy regimen of the treatment group was the same as the control group. Meanwhile, the patients in the treatment group were iv injected with Shenmai Injection (50—100 mL) 3 d before chemotherapy, once daily for 14 d. Two groups were treated for two courses. The life quality was evaluated on the day 1 of the first course and the day 5 after the second course. Results After the treatment, the five dimensions of the two groups in body, role, cognitive, emotional, and social functions, and overall quality of life score were significantly more increased than those before the treatment (P < 0.05), and body, role, and emotional functions of the patients in the treatment group were higher than those in the control group with significant difference (P < 0.05). After chemotherapy, the fatigue, pain, nausea and vomiting scores of the two groups were significantly increased (P < 0.01, 0.05), and scores in the treatment group were lower than those in the control group with significant difference (P < 0.01). In the treatment group, the dyspnea, insomnia, loss of appetite, and constipation scores were lower than those in the control group (P < 0.05). Conclusion Shenmai Injection could improve the life quality of the patients suffered from moderate and advanced stages non-small cell lung cancer treated by chemotherapy.